MA41291A - Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer - Google Patents
Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancerInfo
- Publication number
- MA41291A MA41291A MA041291A MA41291A MA41291A MA 41291 A MA41291 A MA 41291A MA 041291 A MA041291 A MA 041291A MA 41291 A MA41291 A MA 41291A MA 41291 A MA41291 A MA 41291A
- Authority
- MA
- Morocco
- Prior art keywords
- ubique
- pyrrolotriazinone
- usp7
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- IJYHVZICHKCLMQ-UHFFFAOYSA-N imidazo[4,5-d]triazin-4-one Chemical class O=C1N=NN=C2N=CN=C12 IJYHVZICHKCLMQ-UHFFFAOYSA-N 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- BEBRHYJBTAMGRW-UHFFFAOYSA-N pyrrolo[3,2-d]triazin-4-one Chemical compound O=C1N=NN=C2C=CN=C12 BEBRHYJBTAMGRW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098145P | 2014-12-30 | 2014-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41291A true MA41291A (fr) | 2017-11-07 |
Family
ID=55272609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041291A MA41291A (fr) | 2014-12-30 | 2015-12-28 | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10000495B2 (fr) |
| EP (1) | EP3240790A1 (fr) |
| JP (1) | JP2018500377A (fr) |
| HK (1) | HK1246285A1 (fr) |
| MA (1) | MA41291A (fr) |
| WO (1) | WO2016109480A1 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| EP3253765A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thiénopyrimidinones utilisées comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GEP20207161B (en) | 2016-06-10 | 2020-10-12 | Servier Lab | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
| WO2018009812A1 (fr) | 2016-07-08 | 2018-01-11 | Mayo Foundation For Medical Education And Research | Procédés et matériaux de traitement du cancer |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CA3083320C (fr) | 2017-11-29 | 2022-08-16 | Les Laboratoires Servier | Derives de piperidinyl comme inhibiteurs de la protease 7 propre a l'ubiquitine |
| GB201801562D0 (en) | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| EP3870179A4 (fr) | 2018-10-22 | 2022-11-23 | Dana Farber Cancer Institute, Inc. | Inhibition d'usp7 |
| WO2020092528A1 (fr) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1 |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| CN113365696A (zh) * | 2018-12-06 | 2021-09-07 | 阿尔麦克探索有限公司 | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 |
| US20220125760A1 (en) | 2019-02-14 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml) |
| WO2020207352A1 (fr) * | 2019-04-11 | 2020-10-15 | 四川科伦博泰生物医药股份有限公司 | Composés de benzimidazole triazine et leur utilisation médicale |
| EP3965749A4 (fr) * | 2019-05-06 | 2023-06-21 | Valo Health, Inc. | Inhibition de l'usp19 |
| EP3972695A1 (fr) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| EP4110393A1 (fr) * | 2020-02-28 | 2023-01-04 | Immunologik GmbH | Inhibiteurs de désubiquitinases humaines pour le traitement d'infections coronavirales |
| CN113801135B (zh) * | 2020-06-15 | 2025-06-24 | 四川科伦博泰生物医药股份有限公司 | 噻吩并吡唑类化合物，包含其的药物组合物及其用途 |
| EP4373816A1 (fr) * | 2021-07-20 | 2024-05-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs ciblant la protéase spécifique de l'ubiquitine 7 (usp7) |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008217A (en) | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5985863A (en) | 1996-09-12 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| IN151496B (fr) | 1980-02-26 | 1983-05-07 | Chamanlal Jagannath Shishoo | |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JPH02163569A (ja) | 1988-12-14 | 1990-06-22 | Nippon Piston Ring Co Ltd | ピストンリングの計測方法及び装置 |
| JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
| US5124335A (en) | 1991-01-30 | 1992-06-23 | Merck & Co., Inc. | Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US20120165319A1 (en) | 1995-12-20 | 2012-06-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1 beta converting enzyme |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| JP2001524121A (ja) | 1997-05-08 | 2001-11-27 | アグレボ・ユー・ケイ・リミテツド | 殺菌剤 |
| US6444816B1 (en) | 1997-10-27 | 2002-09-03 | Dr. Reddy's Research Foundation | Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof |
| EP1073643B1 (fr) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant |
| NL1011737C2 (nl) | 1999-04-06 | 2000-10-09 | Ct For Immunopharmacology | Verbinding voor het remmen van de influx van polymorphonucleaire leukocyten (PMNs) in een weefsel, werkwijze voor het selecteren van een dergelijke verbinding, een farmaceutisch preparaat en een toepassing van de verbinding. |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US20030153598A1 (en) | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
| US20060183776A9 (en) | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| EP2133078A1 (fr) | 2000-03-03 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Utilisation d'un inhibiteur de la cholinestérase pour le traitement de troubles cognitifs et/ou d'une démence associés à ou provoqués par des tumeurs cérébrales |
| WO2001094350A1 (fr) | 2000-06-07 | 2001-12-13 | Almirall Prodesfarma S.A. | Derives de 6-phenyl-pyrrolo-pyrimidine |
| CN1439008A (zh) | 2000-06-23 | 2003-08-27 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为因子xa抑制剂的1－(杂芳环基－苯基)－稠合吡唑衍生物 |
| JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
| PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
| US20020169175A1 (en) | 2001-02-05 | 2002-11-14 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of heterocyclic compounds |
| US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| WO2003024456A1 (fr) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methodes de traitement et de prevention des migraines |
| WO2003032914A2 (fr) | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Procedes de traitement de la consommation abusive de substances psychoactives a l'aide d'inhibiteurs de la cholinesterase |
| MXPA04008797A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Inhibidores de histona desacetilasa. |
| AU2003228796A1 (en) | 2002-05-01 | 2003-11-17 | Eisai Co., Ltd. | Cholinesterase inhibitors to prevent injuries caused by chemicals |
| US20070053976A1 (en) | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| WO2004034963A2 (fr) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methodes et compositions utilisant des inhibiteurs de la cholinesterase |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| AU2003249477A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| WO2004037176A2 (fr) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones et derives de celles-ci comme inhibiteurs du facteur xa |
| WO2004058727A1 (fr) | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite |
| DE602004007840T2 (de) | 2003-03-18 | 2008-04-10 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren |
| EP1646615B1 (fr) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp |
| RU2358975C2 (ru) | 2003-08-26 | 2009-06-20 | Тейдзин Фарма Лимитед | Пирролопиримидиноновые производные |
| US7557113B2 (en) | 2003-08-26 | 2009-07-07 | Teijin Pharma Limited | Substituted pyrrolo[3,2-d]pyrimidine derivatives |
| US20050148534A1 (en) | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| US20050187147A1 (en) | 2003-09-22 | 2005-08-25 | Newman Michael J. | Compositions and methods for increasing drug efficiency |
| WO2005030705A1 (fr) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibiteurs d'histone deacetylase |
| EP1729761A4 (fr) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | Traitement de cadasil avec des inhibiteurs de la cholinesterase |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| NZ551004A (en) | 2004-04-02 | 2010-07-30 | Prana Biotechnology Ltd | Neurologically-active compounds |
| EP1779867A4 (fr) | 2004-07-01 | 2009-12-02 | Eisai R&D Man Co Ltd | Promoteur de la régénérescence nerveuse |
| US20060135507A1 (en) | 2004-08-13 | 2006-06-22 | Osamu Yokoyama | Therapeutic agent for overactive bladder involved in aging |
| US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
| CA2577275A1 (fr) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf |
| CA2584412C (fr) | 2004-09-14 | 2017-05-09 | Minerva Biotechnologies Corporation | Methodes de diagnostic et de traitement du cancer |
| JP2006176503A (ja) | 2004-11-26 | 2006-07-06 | Tohoku Univ | 脳血管障害を伴うアルツハイマー病治療薬 |
| CN101103032B (zh) | 2004-12-24 | 2011-05-11 | 大日本住友制药株式会社 | 双环吡咯衍生物 |
| JP5000490B2 (ja) | 2005-04-28 | 2012-08-15 | 武田薬品工業株式会社 | チエノピリミドン化合物 |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US7745447B2 (en) | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| CA2633484A1 (fr) | 2005-12-23 | 2007-06-28 | Novartis Ag | Composes heterocycliques condenses utiles en tant qu'inhibiteurs de dpp-iv |
| WO2008024978A2 (fr) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Dérivés de benzène, de pyridine et de pyridazine |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| US8586619B2 (en) | 2007-03-12 | 2013-11-19 | Vm Therapeutics Llc | Agents of calcium ion channel modulators |
| WO2008113255A1 (fr) | 2007-03-16 | 2008-09-25 | The Institute Of Radiation Medicine, Academy Of Military Medical Sciences, Pla | Dérivés de benzamide avec activité antiproliférative, leurs préparations pharmaceutiques |
| WO2008116053A2 (fr) | 2007-03-20 | 2008-09-25 | Trustees Of Tufts College | Composés chimiothérapeutiques activés par la protéine fap |
| CA2685753A1 (fr) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Derives bicycliques de pyrimidine en tant que bloqueurs des canaux calciques |
| RU2341527C1 (ru) | 2007-07-17 | 2008-12-20 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ |
| RU2345996C1 (ru) | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения |
| JP5498392B2 (ja) | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| WO2009124259A1 (fr) | 2008-04-04 | 2009-10-08 | Cv Therapeutics, Inc. | Dérivés de pyrrolotriazinone pouvant être utilisés à titre d'inhibiteurs de stéaroyl-coa désaturase |
| AU2009282480B2 (en) | 2008-08-11 | 2015-05-07 | Children's Medical Center Corporation | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| US20110082158A1 (en) | 2008-10-01 | 2011-04-07 | Aleem Gangjee | Selective proton coupled folate transporter and folate receptor, and garftase and/or other folate metabolizing enzymes inhibitor compounds and methods of using the same |
| JP2012513481A (ja) | 2008-12-23 | 2012-06-14 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ネクロトーシスの小分子阻害剤 |
| AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| US8927718B2 (en) | 2009-08-26 | 2015-01-06 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| US8841289B2 (en) | 2009-10-13 | 2014-09-23 | Merck Sharp & Dohme B.V. | Heterocyclic derivatives |
| KR101590764B1 (ko) | 2009-11-13 | 2016-02-02 | 삼성전자주식회사 | 컴퓨팅 시스템 및 컴퓨팅 시스템의 메모리 관리 방법 |
| US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
| US8575114B2 (en) | 2010-03-23 | 2013-11-05 | Albany Molecular Research, Inc. | SGLT-2 inhibitors, methods of making them, and uses thereof |
| US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012075393A2 (fr) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
| US20130303551A1 (en) | 2011-01-10 | 2013-11-14 | Nicholas D. Adams | Pyrimidinone derivatives as fatty acid synthase inhibitors |
| GB201107768D0 (en) | 2011-05-10 | 2011-06-22 | Univ Manchester | Riboswitches |
| EP2565186A1 (fr) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| TW201348226A (zh) | 2012-02-28 | 2013-12-01 | Amgen Inc | 作為ｐｉｍ抑制劑之醯胺 |
| GB201205164D0 (en) | 2012-03-23 | 2012-05-09 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP2938610A2 (fr) * | 2012-12-28 | 2015-11-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Inhibiteurs du complexe usp1/uaf1 désubiquitinase et leurs utilisations |
| KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체 |
| CN103833646A (zh) | 2014-02-28 | 2014-06-04 | 广东工业大学 | 一种脂肪氨基取代喹唑啉酮衍生物及其制备方法和应用 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| EP3253765A1 (fr) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thiénopyrimidinones utilisées comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine |
| US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
-
2015
- 2015-12-28 MA MA041291A patent/MA41291A/fr unknown
- 2015-12-29 WO PCT/US2015/067781 patent/WO2016109480A1/fr not_active Ceased
- 2015-12-29 JP JP2017535009A patent/JP2018500377A/ja active Pending
- 2015-12-29 HK HK18105708.2A patent/HK1246285A1/zh unknown
- 2015-12-29 US US14/982,131 patent/US10000495B2/en active Active
- 2015-12-29 EP EP15830954.2A patent/EP3240790A1/fr not_active Withdrawn
-
2018
- 2018-05-24 US US15/988,790 patent/US10351571B2/en active Active
-
2019
- 2019-06-24 US US16/449,599 patent/US10981915B2/en active Active
-
2021
- 2021-04-14 US US17/230,603 patent/US11795171B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180339991A1 (en) | 2018-11-29 |
| US20190308980A1 (en) | 2019-10-10 |
| US10981915B2 (en) | 2021-04-20 |
| US10000495B2 (en) | 2018-06-19 |
| US20160185786A1 (en) | 2016-06-30 |
| JP2018500377A (ja) | 2018-01-11 |
| EP3240790A1 (fr) | 2017-11-08 |
| WO2016109480A1 (fr) | 2016-07-07 |
| US10351571B2 (en) | 2019-07-16 |
| US20220033403A1 (en) | 2022-02-03 |
| HK1246285A1 (zh) | 2018-09-07 |
| WO2016109480A8 (fr) | 2016-10-27 |
| US11795171B2 (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41291A (fr) | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer | |
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA45406A (fr) | Inhibiteurs d'ezh2 pour traiter le cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| EP3368559A4 (fr) | Compositions et méthodes pour le du traitement du cancer | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| SG10201908028SA (en) | Cyclopropylamines as lsd1 inhibitors | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| EP3400011A4 (fr) | Combinaisons anti-cd20 pour le traitement des tumeurs | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| EP3541417A4 (fr) | Immunothérapies d'association pour le traitement du cancer | |
| EP3490561A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA49841A (fr) | Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine | |
| EP3443962A4 (fr) | Dérivé de quinoline pour le traitement du cancer de l'estomac | |
| EP3347025A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |